Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

Leishmaniasis is a vector borne protozoan disease and it remains a major public health
problem world-wide. Lack of an effective vaccine and vector control program makes the …

Miltefosine is the only recognized oral agent with potential to treat leishmaniasis. Miltefosine
had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nepal, and …

Visceral leishmaniasis (VL) is a vector-borne chronic infectious disease caused by the
protozoan parasite Leishmania donovani or Leishmania infantum. VL is a serious public …

Background With widespread resistance to antimonials in Visceral Leishmaniasis (VL) in the
Indian subcontinent, Miltefosine (MIL) has been introduced as the first line therapy …

Post‐kala‐azar dermal leishmaniasis (PKDL) is a dermal sequela of visceral leishmaniasis
(VL), reported mainly from two regions–Sudan in eastern Africa and the Indian subcontinent …

Miltefosine (hexadecylphosphocholine) is the first oral antileishmanial drug. In this study, we
addressed the question whether miltefosine-resistant Leishmania donovani promastigotes …

A series of triphenyl Sb (V) and Bi (V) α-hydroxy carboxylato complexes of the general
formula [MPh3 (O2CROH) 2] and [MPh3 (O2CRO)] have been successfully synthesised and …

Visceral leishmaniasis (VL) is a severe and often fatal form of leishmaniasis caused by
Leishmania donovani in the Indian sub-continent. Post Kala-azar Dermal Leishmaniasis …

Background Post–kala-azar dermal leishmaniasis (PKDL) is a dermal complication of
visceral leishmaniasis. Oral miltefosine (MF) is the first-line treatment for PKDL patients in …